

**Effective Solutions for  
Problems experienced  
by Women at the  
Menopause**

**Dr Deirdre Lundy**

---

**ICGP AGM**

**May 25, 2018**

**Dublin Convention Centre**

A decorative graphic of a feather, rendered in a light beige color, is positioned on the left side of the slide. It has a central rachis with numerous barbs extending outwards, creating a fan-like shape.

# Declaration of Financial Interests or Relationships

Speaker Name: DEIRDRE LUNDY

I have the following financial interest or relationship(s)  
to disclose with regard to the subject matter of this  
presentation:

Speaker for: Mylan, Bayer, Consilient, MSD, Amgen

# Definitions and Terms



The “MENOPAUSE” is defined as the LAST day of the LAST menstrual period and so can only be identified retrospectively. It is the post reproductive phase of a woman’s life aka *“reproductive senescence”*

But patients & HCP’s all use the term **“In the Menopause”** or **“In the Change”** to identify the symptomatic phase of the transition from fertile to post fertile stage of life

More correctly WE should use the term **Peri menopause** or **Climacteric**



# PERIMENOPAUSE or “CLIMACTERIC”

“MENOPAUSE TRANSITION”

Symptoms often precede Final Menstrual Bleed by Years but typically in 40's.

Don't out rule menopause just because patient still has periods so

Often juggling Contraception needs and Menopause symptoms

# The Stigma of Menopause

Women are living longer and can often spend as much time in the post reproductive phase of their lives as they did in the first 50 years ! Throughout history we see negative associations surrounding the menopause & later life



We as clinicians can have a positive impact on the approach of the second 50 years !

# Menopause Consultations are becoming more common lately

**NICE** National Institute for  
Health and Care Excellence



**Menopause: diagnosis and management**

NICE guideline  
Published: 12 November 2015  
[nice.org.uk/guidance/ng23](https://www.nice.org.uk/guidance/ng23)

- **NICE finally published the comprehensive guidelines for the Management of Menopause Disorder and Prescribing HRT 2015**
- **Nothing New in it actually**
- **Same criticisms of the WHI and our response to it**
- \* **Reassurances again about early intervention and long term use**



# What happens at the Peri Menopause ?

# The menstrual cycle in the early/pre Menopause Transition

---



- The antral follicle count drops as menopause approaches  
**(AMH levels become undetectable within 5 years of the FMP)**
- The lower amount of granulosa cells means **less Inhibin B** is produced
- **Less Inhibin B** means less negative feedback on the pituitary and **FSH levels rise in the early follicular phase** which results in
- **Multiple dominant follicle development** ( or overactive single dominant follicles ) and this creates
- More E2 in the early follicular phase so the LH surge occurs earlier, ovulation occurs earlier so the **cycle is SHORTENED**



# Hormonal Changes During Menopause Transition

- Accelerated follicle development starts at 37-38 yrs and the antral follicle count drops  
**(AMH levels become undetectable within 5 years of the Final Menstrual Period)**
- The lower amount of granulosa cells means **less Inhibin B** which causes less negative feedback on the pituitary **and FSH levels rise in the early follicular phase** which results in
- **FSH ↑ 20-40 X.... But this is unpredictable & may fluctuate**
- LH ↑ 20 X
- Circulating levels of Oestradiol fall to 10-20 pg/ml
- Dominant circulatory estrogen becomes **oestrone** *most of which is derived from peripheral conversion of androstenedione in fatty tissue*
- Testosterone levels fall by 25%
- Androgen : Estrogen ratio increases

# Why Peri menopausal Sex Hormone Levels aren't an acceptable diagnostic tool



**& Symptoms often occur**

---



# PERI-MENOPAUSAL SYMPTOMS

## PHYSICAL

- **NIGHT SWEATS & HOT FLUSHES**
- **MENSTRUAL CHANGES: Menorrhagia, Irregularity**
- **LOSS OF VAGINAL ELASTICITY & LUBRICATION**
- **DECREASE IN METABOLISM**
- **Increase in incidence of METABOLIC SYNDROME**
- **HAIR & SKIN CHANGES**
- **JOINT COMPLAINTS**
- **BLADDER COMPLAINTS**

## EMOTIONAL

- **DEPRESSION,**
- **MOOD SWINGS**
- **ANXIETY**
- **TIREDDNESS**
- **MEMORY LOSS**
- **CONCENTRATION LOSS**
- **LOSS OF LIBIDO**
- **PMS-TYPE SYMPTOMS**

# Menopause

40 yrs

50 yrs

60 yrs



Vasomotor Symptoms  
Sleep Disorders  
Mood Changes

Urogenital Atrophy  
Dyspareunia

Menstrual Disorders

Osteoporosis  
Atherosclerosis  
Coronary Heart Disease  
Cerebrovascular Disease

# MANAGEMENT OF THE PERI MENOPAUSE

- Take a thorough history and ALWAYS ENQUIRE DIRECTLY ABOUT  
**Incontinence**  
**Sexual Dysfunction**
- EXCELLENT OPPORTUNITY FOR A GENERAL MEDICAL EXAMINATION but not necessary prior to Rx HRT

**Blood pressure, BMI**

**Optional Breast/ Pelvic examination +/- SMEAR TEST and MAMMOGRAPHY if required**

- COUNSEL AND ADVISE wrt  
**Diet & Exercise, Contraception, Health Screening**

**Offer the OPTION OF HORMONE REPLACEMENT THERAPY**



# HORMONE REPLACEMENT THERAPY 'HRT'

---

Replacing the FALLING levels of  
endogenous Oestrogen with small doses of  
exogenous Oestrogen+/-additional  
Progestagen

# HRT & MISINFORMATION

> 50 % of women say their symptoms are SEVERE

But

Patients either don't attend at all or refuse to even discuss HRT because of the general consensus that HRT causes Breast Cancer (among other things)

This fear is NOT supported by reliable data.

**So let's look at that data:**



# **HRT: BENEFITS vs UNCERTAINTIES**

Worries about HRT are based on three main studies:

---

- 1. Heart Estrogen/Progestin Replacement Study (1998 : USA)**
- 2. Women's Health Initiative (2002 : USA )**
- &**
- 3. Million Women Study (2003 : UK )**

# WOMENS HEALTH INITIATIVE (WHI) USA JAMA 2002

---

- Largest randomised clinical trial

(> 68,000 women) conducted to determine if older, post menopausal women might obtain Cardiovascular, Malignant & Osteoporosis Disease Protection from HRT

- *Should* have been higher quality study than the other two (Level I Evidence)

# WHI



BUT.....

- Enrolees were aged from 50-79 ( **average 63yo with only 3.5 % of participants were in 50-54 group** )

**Women with severe symptoms were excluded.**

**Women with previous serious CVD were included.**

Only used CEE .625mg (E only) for the hysterectomised ladies (WHI- ERT arm) or CEE .625mg + MPA 2.5mg (E+P) for the non- hysterectomised (WHI- PERT arm)

# WHI BREAST CANCER DATA

WHI initially concluded that Breast Cancer Rates in relation to HRT were:

- Never used ..... **16** cases/ 1000 women/ 5 yrs treatment
- E only..... **16** cases/1000 women/5 yrs treatment
- EE+ MPA..... **20** cases/1000 women/5 yrs treatment

.. risk returns to normal within 5 years of discontinuing

**RATES OF PRE INVASIVE BREAST CA & BREAST CA MORTALITY WERE THE SAME FOR PLACEBO & HRT GROUPS**

When they published this **breast cancer data** they wrote that:

***‘a small increased RR in Breast CA (1.26) was observed which did not reach statistical significance’***

*(Similar to what we saw in the MWS & what we were already telling the patients)*

- BUT the following year a JAMA editorial reported the WHI study demonstrated that ....

**Breast CA rates were “markedly increased”  
in the HRT group!**

How did that happen!?

# Relative Risk of Breast Cancer as seen in Meta analyses

Relative risk data can seem more important than they are.

Which of the following gives women the least relative risk of developing breast cancer?

- Eating one serving of French fries every week.
- Eating more than a quarter of a grapefruit every day.
- Working night shifts.
- Taking antibiotics.
- Using an electric blanket if you are an African American.
- Taking estrogen- only HRT to alleviate the effects of menopause; WHI data

Of course.... HRT is the “safest”

FACTOR/ Study	RR
<b>HRT (Conj EE) WHI 2002</b>	<b>.77</b>
<b>FRIES</b> <i>International Journal of Cancer 2006</i>	1.27
<b>GRAPEFRUIT</b> <i>British Journal of cancer 2007</i>	1.3
<b>NIGHT SHIFT WORK</b> <i>European Journal of Cancer 2005</i>	1.51
<b>ANTIBIOTIC USE</b> <i>JAMA 2004</i>	2.07
<b>ELECTRIC BLANKET USE</b> <i>American Journal of Epidemiology 2003</i>	<b>4.9</b>

# Understanding the risks of breast cancer

Women's Health Concern

A comparison of lifestyle risk factors versus Hormone Replacement Therapy (HRT) treatment.

**Difference in breast cancer incidence per 1,000 women aged 50-59.**

Approximate number of women developing breast cancer over the next five years.

NSC Guidelines Assessment  
Diagnosis and Management  
November 2011

**23 cases of breast cancer diagnosed in the UK general population**



**An additional four cases in women on combined hormone replacement therapy (HRT)**



**Four fewer cases in women on oestrogen only Hormone Replacement Therapy (HRT)**



**An additional four cases in women on combined hormonal contraceptives (the pill)**



**An additional five cases in women who drink 2 or more units of alcohol per day**



**Three additional cases in women who are current smokers**



**An additional 24 cases in women who are overweight or obese (BMI equal or greater than 30)**



**Seven fewer cases in women who take at least 2 1/2 hours moderate exercise per week**



Women's Health Concern

www.womenshealthconcern.org.uk  
Reg Charity No: 109488  
Company Reg No: 1482624

Women's Health Concern is the patient arm of the BMS.  
We provide an independent service to advise, reassure and educate women of all ages about their health, wellbeing and lifestyle concerns.

Go to [www.womens-health-concern.org](http://www.womens-health-concern.org)

BMS  
British Menopause Society

www.bmsociety.org.uk  
Reg Charity No: 309204  
Company Reg No: 0270629




# So what do we tell the patients ?

- HRT USE BEFORE THE AGE OF 50 YO CARRIES **NO ADDITIONAL RISK OF BREAST CA DETECTION** (*don't discourage access to HRT to the younger patients particularly those who go through **PREMATURE MENOPAUSE***)
- HRT USE BETWEEN 50-54 YOA IS LINKED TO A SMALL ADDITIONAL RISK OF BREAST CA
- HRT USE **OVER 54 YOA** IS LINKED TO AN **INCREASED BREAST CA RISK-going** from 30 cases/10,000 women who never used it to 38 cases/10,000women  
( Keep the dose low –minimum effective for symptoms. Mind the type(s) you prescribe: tibolone, 17 beta, Dydro,Neta, Drospir vs MPA ??, and the routes of administration, transdermal??)
- **EXAMINE REGULARLY**
- **REMEMBER ...MORE WOMEN DIE FROM OSTEOPOROTIC FRACTURE-RELATED DISEASE THAN FROM CANCERS OF THE BREAST , UTERUS & CERVIX COMBINED...BUT OFTEN NOT LISTED ON DEATHS CERTS**

*Mortality after admission to hospital with fractured neck of femur: database study*

*BMJ 2002;325:868*



---

**What about the other aspects  
of the WHI study.... CVD &  
Thrombosis ?**

# WHI + *Cardiovascular* SUMMARY

Rossouw JAMA 2007

## EFFECTS PER 10,000 WYRS of E only Use:

10 Fewer DEATHS

10 Fewer CHD Events

2 Fewer STROKES

## EFFECTS PER 10,000 WYRS of E+P Use:


9 Fewer DEATHS

5 More CHD Events in >60's in the 1<sup>st</sup> year\*

5 More STROKES in >60's in the 1<sup>st</sup> year\*


**NO OVERALL ↑ IN CVD OVERALL\***

\*HRT: Putting Benefits & Risks into Perspective M.Warren MD; Columbia Univ Med School




**So what is the relationship  
between Menopause, HRT &  
the Cardiovascular System ?**

# Consequences of Menopause on the Cardiovascular system




# Effect of Hormone Therapy on Atherosclerosis Varies With Stage of Reproductive Life

← Premenopause →




15-25 yrs  
25-35 yrs  
**Benefits of  
Endogenous E<sub>2</sub>**

Perimenopause



35-45 yrs  
45-55 yrs  
**Benefit of HRT**


← Post menopause →




55-65 yrs  
65-75 yrs  
**>10 years without HRT**

# Timing is Critical

**Early atherogenesis**



**Established atherosclerosis**



**Beneficial effects of HRT**

- ↑ Vasodilation
- ↑ Nitric oxide
- ↓ Endothelin
- ↑ Cox-2
- ↓ Inflammatory activation
- ↑ Nitric oxide
- ↓ CAMs
- ↓ MCP-1, TNF- $\alpha$
- ↓ Lesion progression
- ↑ Nitric oxide
- ↓ Inflammatory cell adhesion
- ↓ LDL oxidation/binding
- ↓ Platelet activation
- ↓ VSMC proliferation

**Altered biology of HRT**

- ↓ ER expression, function
- ↓ Vasodilation
- ↑ Inflammatory activation
- ↑ Plaque instability
- ↑ MMP
- ↑ Neovascularization

# So what do we tell the patients ?

- Women with known CVD ( Angina, MI, etc ) should avoid HRT as should women > 10 years past the menopause
- Women with a very strong Family Hx of CVD (e.g.. First degree pre menopausal female relative ) should consider some CV screening in the peri- Menopausal years ( BP monitoring, ECG, fasting Lipids, Glucose, etc )
- Women < 10 years from the menopause or under 60 yo are in fact derive some cardio-protection from HRT use but further studies need to be done.

**ALL THIS SUPPORTED & REPEATED BY NICE 2015**



# HRT & Thrombosis

- WHI did show ↑ risk in VTE within the first 2 years (although the absolute risk remained low) particularly for the E+ P group
- PE rates were NOT increased
- Observational data also suggest that **Transdermal HRT may be less thrombogenic than Oral NICE**
- Is MPA thrombogenic??
- Should we be favouring **micronised progesterone ??? NICE**

# So what do we tell the patients ?

- In the first year or two from starting oral HRT the risk of getting a DVT is slightly elevated
- HRT should be avoided in women with a current or recent past Hx of DVT & caution with women who had VTE around pregnancy or while on the COCP
- Women with a strong FHx of or multiple risk factors for DVT might benefit from Haematological review before Rx and then may be safer on **Transdermal products**

# CONTRAINDICATIONS/ PRECAUTIONS:

## ABSOLUTE

- Suspected Breast or Endometrial cancer
- Ischemic Heart disease
- Undiagnosed abnormal genital bleeding
- Active TE disorder
- Active liver or gall bladder disease
- Pregnancy or Breast feeding

## RELATIVE

- Migraine headache
- History of liver or gall bladder disease
- History of Endometrial cancer
- History of TE events

**FAMILY HISTORY OF BREAST CA IS NOT AN ABSOLUTE CONTRAINDICATION  
to HRT USE !!!**

**CONTROLLED HYPERTENSION IS also OK**

# General information for women near the Menopause

---

- Consider screening for hypothyroidism, anaemia, primary depression – all common around the menopause & can present as perimenopause-like symptoms
- Contraception !!!
- Address MODIFIABLE factors:

# Health Promotion: Diet

---

- Encourage oily fish, low GI fruits & veg, whole grains, soya, legumes
- Discourage excess red meat & simple sugars
- Vitamin D intake of at least 400mIU (10 microg) /day – consider supplements
- Calcium 700-1200mg /day ideally via diet

# Health Promotion: Exercise

---

## Regular Exercise :

- Decreases premature death, CVD, DM, HTN, CA colon & Obesity.
- Has a beneficial effect on Bone, Muscle & can reduce the risk of falling by improving strength, flexibility & balance.
- Improves psychological symptoms
- Decreases LDLs, & Increases HDLs

## The WHO recommends:

- 75 min vigorous or 150 min moderate aerobic exercise / week

# Health Promotion: Weight Management

---

Menopause can bring weight gain

- Metabolic slow down
- Shift from Gluteo- femoral to Central adipose deposition
- Tiredness & Low Mood promote increased calorie intake

# Health Promotion: Reducing Alcohol

---

- Moderate alcohol intake (< 2 units/day ) is linked to lower mortality than abstinence – although the link is unclear
- **Breast Cancer risk** however is **higher in women who consume even low levels of alcohol** ( compared to abstinent women )
- Heavy alcohol consumption is linked to increased rates of breast cancer, low bone density, falls & fractures and more



# Health Promotion: Smoking Cessation

---

12 mos after smoking cessation, the risk of CVD death is reduced by 50% (INTERHEART Study)

Smoking cessation is shown to be more likely when:

- the GP intervenes &/or
- Nicotine replacement is used



# IRISH OPTIONS in HRT PRESCRIBING

---

# CHOICES IN HRT in the Irish MIMS

PRESCRIBING INFO OFTEN INACCURATE !!

20 products: 17 are HRT + vagifem + some progestins

## ESTROGEN

- Oral
- Transdermal Patch
- Transdermal Gel
- IntraVaginal Gel
- IntraVaginal Pessary
- IntraVaginal Ring
- IntraNasal Spray
- IntraAbdominal Implant

## PROGESTAGEN

- Oral
- Transdermal Patch
- IUS (Mirena)
  
- Plus.....**TIBOLONE**; a synthetic steroid whose metabolites have Oestrogenic, Progestagenic & Androgenic properties

# CURRENT BLEED-PRODUCING HRT in MIMS

**FEMOSTON 2/10** -Sequential Oral  
2mg Oestradiol +/- 10mg. Dydrogesterone

**Femoston 1/10**- Sequential Oral  
1mg Oestradiol +/- 10mg. Dydrogesterone

**NOVOFEM** -Sequential Oral  
1mg. Estradiol +/- 1mg. Norethisterone

ESTALIS SEQUI-Sequential Transdermal  
Estradiol 50 microg. +/- 250microg. Norethisterone

ESTRACOMBI-Sequential Transdermal  
50microg. Oestradiol +/- 250microg. Norethisterone

**PREMPAK-C**- Sequential Oral  
Conj Oestrogen 0.625 & 1.25mg. +/-  
Norgestrel 0.15mg.

**TRISEQUENS**- Sequential Oral  
Estradiol 2 & 1mg +/- 1mg. Norethisterone

NUVELLE-Sequential Oral  
2mg. Oestradiol +/- 75microg. Levonorgestrel

**PREMIQUE CYCLE 10** - Sequential Oral  
Conj. Equine Oestrogen. 625mg. +/- 10mg. MPA

PLUS...

**UTEROGESTAN**- Oral Micronised Progesterone 100mg. NOT in MIMS  
& **DUPHSTON** Oral Dydrogesterone 10mg



# CURRENT NON-BLEED -PRODUCING HRT

**ACTIVELLE** – Continuous Combined Oral  
1mg. Estradiol + .5mg Norethisterone

**ANGELIQ**- Continuous Combined Oral  
1mg.Estradiol + 2mg.Drospirenone

**EVOREL CONTI** -ContComb.Transdermal  
50microg.Oestradiol + 170microg.Norethisterone

**FEMOSTON-CONTI 1/5** -Cont.Comb. Oral  
1mg Estradiol + 5mg.Dydrogesterone

**FEMOSTON-CONTI 0.5/2.5**-Cont.Comb. Oral  
.5mg Estradiol + 2.5mg.Dydrogesterone

**INDIVINA** - Cont.Comb. Oral

1 mg. Oestradiol

+Medroxyprogesterone acetate(MPA);2.5 or 5mg



**KLIOGEST**- Cont.Comb. Oral

2mg.Oestradiol/ 1mg.Norethisterone

**PREMIQUE** - Cont.Comb. Oral

Conj Oestrogen .625mg + 5mg. MPA

**& LIVIAL-2.5mg.** Tibolone..  
Synthetic steroid, Gonadomimetic



# CURRENT OESTROGEN-ONLY

Hysterectomised Women or Mirena IUS < 5 yrs. old

**CLIMARA**-Transdermal Estradiol patch 50microg/day-(weekly)

**DIVIGEL**-Transdermal .1% Estradiol gel

**ESTROFEM** - Oral 2mg.Estradiol

**EVOREL** -Transdermal 50microg. Estradiol

**FEMATAB** -Oral 2 mg. Estradiol

**FEMATAB** -Oral 1mg. Estradiol

**ESTRADOT**-Transdermal Estradiol 37.5, 50. 75 & 100 microg.

**PREMARIN** - Oral Conj. Equine Oestrogen .625 & 1.25 mg.

*AERODIOL-Intranasal Estradiol spray*

*OESTROGEL - Transdermal 17beta-Oestradiol 1.5mg.*

*ESTRADERM TTS -Transdermal Estradiol 25, 50 & 100microg.*

\*\*\*\*\*

**VAGIFEM** - Intra Vaginal Estradiol .010mg Minimal systemic absorption.

**Ideal for women with local symptoms- unlikely to have direct influence on Breast, CVD, etc.**





**Please..... offer  
VAGIFEM/ OVESTIN/ BLISSEL to all women  
( & disregard the SmPC ! )**

**Intra Vaginal Estradiol .010mg allows Minimal systemic absorption** so is Ideal for women with local symptoms- unlikely to have direct influence on Breast, CVD, etc..

**SHOULD BE OFFERED TO ALL WOMEN AT WHATEVER DOSE  
( max 5 a day ) /INTERVAL THEY REQUIRE WITH NO  
RESTRICTION TO DURATION OF USE**

**Twice weekly applications will, in one year (104 pessaries), result in less systemic exposure than a single PO HRT tablet**

# Other Menopause Preparations

– Progestogens ( ‘Duphaston’ is oral dydrogesterone, Mirena IUS, ‘Uterogestan’ is oral micronised progesterone) & previously an Androgen (‘Intrinsa’ testosterone patch)

and

Testosterone ( “Testim” or “Testogel”)

– “S.E.R.M.”s



***S.E.R.M.s***  
***SELECTIVE ESTROGEN***  
***RECEPTOR MODULATORS***

– **E<sub>2</sub>-LIKE EFFECTS**

Increases BONE DENSITY

Decreases LDLs

Increases TE risk

– **TAMOXIFEN-LIKE EFFECTS**

Decreases BREAST CA RISK

Decreases ENDOMETRIAL CA RISK

Increases VASOMOTOR SYMPTOMS

# TSECs

---

- Combination of SERM and Oestrogen
- Currently offering “Aprela” & “Duavive” in the USA & UK, resp
- “Duavive” in the UK (0.45 mg of CEE and bazedoxifene acetate equivalent to 20 mg bazedoxifene )
- Useful for women with unassuageable HRT fears maybe ??
- No NICE guidance for these as yet in the UK

# “DUAVIVE”

---

- Premarin .045 mg +
- Bazedoxifene 20 mg ( “Conbriza”)  
SERM
- Licensed in UK
- Still caution after breast cancer treatment but might be safer than E+P



# “Osphena” a Tissue Selective Estrogen Complex

---



- Ospemifene 60mg is a new TSEC
- It has an E2 like impact on the vaginal epithelium; building vaginal wall thickness which in turn reduces the pain associated with dyspareunia
- **Like other SERMs it reduces BREAST Cancer risk & can be Rx after Chemo/Radio Tx done**
- Approved by the US FDA in February 2013
- Not yet licensed in Ireland but has a European License

# What about replacing Testosterone ?

- Menopausal ovarian failure results in less circulating androgen in women
- This may cause low mood, energy, libido but clinical trials are **LIMITED**
- No longer able to Rx female strength testosterone (“Intrinsa” twice weekly patches )
- Consider “Testim” or “Testagel “ but use 1/7 to 1/10 the usual daily dose for men, debate as to whether they should be offered before post Menopause
- Testosterone can impact SHBG so Monitor Free Androgen Index if no response



# Hormone therapy in women at high risk of breast cancer

- ▶ Family history has **no additive impact on breast cancer risk with HRT use**<sup>1,2</sup> although women with gene mutations are at vastly increased lifetime risk of breast cancer
- ▶ HRT use and family history had **independent and non interacting risk factors** for breast cancer in WHI<sup>3</sup>
- ▶ Long term observational studies have reported no extra risk for those using HRT with a family history of breast cancer
- ▶ HRT following risk reduction surgery appears not to increase risk<sup>4,5</sup>
- ▶ HRT in such women should use minimal progestogen and ideally MICRONISED progesterone or dydrogesterone

1. Rippy L Marsden J *Climacteric* 2006;9:404-15

2. Sellars T et al *Ann Intern Med* 1997;127:973-80

3. Gramling R et al *Epidemiology* 2009;20:752-6

4. Rebeck T et al *J Clin Oncol* 2005;23:7804-10

5. Eisen J et al *J Nat Cancer Inst.* 2008;100:1361-67



# **Alternatives to HRT in Menopause Symptom Care**

# Alternative Therapies: Flushes & Sweats: Alpha Agonists

**CLONIDINE HCl 50-75 microg BD**


**Alpha adrenergic agonist**

**Licensed for Migraine & VSM symptoms of  
the Menopause**

**(can be used for HTN but at much higher  
doses)**

**It widens the “thermo-regulatory zone “**

**Can cause insomnia, dry mouth, drowsiness**



# Alternative Therapies: Flushes & Sweats: The Pill

- COC; Combined Oral/TD/TV Contraception
- Much larger quantities of more potent Estrogen & Progestins
- Should provide full VMS relief & **is CONTRACEPTIVE**
- Consider Cat 3 & 4 risks though
- May prefer Zoely/Qlaira



# Alternative Therapies: Flushes & Sweats: Seroxat SSRI

- Selective Serotonin Reuptake Inhibitors
- 10mg Seroxat ( paroxetine ) was found to reduce VMS in women on Tamoxifen<sup>1</sup>
- Obviously may help with low mood in higher doses
- Good for women with personal history of breast CA



<sup>1</sup> Nelson HD, Vesco KK, Haney E, et.al. Nonhormonal therapies for menopausal hot flashes: systematic review & meta- analysis. JAMA 2006; 295:2057-71

# **Alternative Therapies: Flushes & Sweats: Gabapentin**

- NICE says 900mg daily of GabaP has been shown to reduce VMS by approx 50%**
- may be of use in women with breast cancer**

# Alternative Therapies: Flushes & Sweats: CBT & Mindfulness

- Cognitive Behavioural Therapy has been found beneficial over placebo in several aspects of Perimenopausal management including VMS relief\*
- Mindful Meditation Practice is recommended by NICE for help with low mood & anxiety

\* (MENOS 2)

# Complimentary & Herbal Therapies

– Phyto Estrogens: so far *not proven superior to placebo in RCT*

Isoflavones are found in Soya, Red Clover & Chick Peas

Lignans are found in Bran, Flax, Legumes

– Herbal Remedies (all are probably safe but not yet proven effective)

e.g. Black Cohosh, Ginseng, EP oil, Dong Quai, Gingko biloba, Sage, Wild Yam,

St John's Wort (beware LEI activity)

– Vaginal interventions: moisturisers, lubricants, vaginal LASER rejuvenation

– “Bio Identical Hormones” + saliva testing, compounding pharmacies – unregulated and not recommended by NICE



# Keeping Updated

[www.icgp.ie](http://www.icgp.ie) (womens health)

[www.gpbuddy.ie](http://www.gpbuddy.ie)

[www.thebms.org.uk](http://www.thebms.org.uk)

[www.womenshealthconcern.org](http://www.womenshealthconcern.org)



# "GP BUDDY"



<https://www.gpbuddy.ie/go/education>


# PATIENT SUPPORT & REASSURANCE

**The British Menopause Society** has good publications; membership is required (£100 at [www.bms.org.uk](http://www.bms.org.uk)) - well worth it !

**Menopause Matters** website, run by Dr Heather Currie, has some useful recommendations, registration is free  
see: [www.menopausematters.co.uk](http://www.menopausematters.co.uk)

**Primary Care Women's Health Forum** Is a UK charity that works with the NHS on all aspects of health promotion offering **free publications & factsheets** on Menopause & HRT see [www.pcwf.co.uk](http://www.pcwf.co.uk)

I'M  
STILL  
HOT,  
IT JUST  
COMES IN  
FLASHES  
NOW



SHE WAS STARTING TO WONDER IF HER  
HRT DOSE NEEDED CHANGING!

